What manufacturer is Avatrombopag/Sucoxin made by?

Avatrombopag/Avatrombopag, trade name DOPTELET, is an important drug mainly used to treat thrombocytopenia associated with chronic liver disease. The original manufacturer of the drug is the Japanese company AkaRx Inc. The company has strong R&D capabilities and a strict quality control system to ensure the efficacy and safety of the drug.

Avatrombopag is an orally administered thrombopoietin (TPO) receptor agonist, which mimics the biological effect of TPO in stimulating megakaryocyte development and maturation, resulting in an increase in platelet counts. In two clinical studies of patients, ADAPT-1 and ADAPT-2, avatrombopag was shown to be effective in increasing platelet counts, reducing platelet transfusions, and resuscitating bleeding procedures while undergoing invasive surgeries.

It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo surgery, and by the European Medicines Agency (EMA) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled for invasive surgery. It is also indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to previous treatment.

Avatrombopag (Sucoxin) has been included in the National Reimbursement List after being launched in China, which has greatly reduced the financial burden on patients and enabled more patients to benefit from this innovative drug. In the overseas market, in addition to original drugs, there are also some generic drugs. The prices of these generic drugs are relatively low, but the efficacy and safety may vary depending on the manufacturer and manufacturing process. For example, Lao pharmaceutical factories (Lucius Pharmaceuticals, ASEAN Pharmaceuticals, United Pharmaceuticals), Bangladeshi pharmaceutical factories (Ziskar Pharmaceuticals, Yaopin International), etc. provide patients with more treatment options and economic support.